CMD-003 consists of patient-derived (autologous) Epstein-Barr virus (EBV)-specific T cells. The T cells specifically target four EBV epitopes (LMP1, LMP2, EBNA and BARF1).

EBV infects more than 90%1 of the human population on a latent basis and is connected to a variety of cancers. Cell Medica is developing CMD-003 for the treatment of patients with non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) as well as nasopharyngeal carcinoma (NPC) and post-transplant lymphoproliferative disease (PTLD).


Eligible patient population

Non-Hodgkin lymphoma (NHL) is a form of blood cancer that affects 385,7002 patients each year worldwide, leading to 200,0002 deaths.

Hodgkin lymphoma (HL) is a distinctly different from NHL and affects around 66,0002 patients every year, leading to 25,5002 deaths worldwide.

EBV is also associated with nasopharyngeal carcinoma (NPC), a disease which affects around 87,0002 people worldwide. NPC occurs most frequently in Southeast Asian populations, where it is more than 20 times as common in men and 10 times as common among women compared with the rest of the world3.

Post-transplant lymphoproliferative disorder (PTLD) is a disease that often occurs after solid organ transplantation, but may also occur after hematopoietic stem cell transplantation (HSCT). It is strongly associated with EBV4 and estimates show that together the United States and Europe will see approximately 1,600 cases annually5.

The development of CMD-003

The initial clinical development of CMD-003 focused on extranodal natural killer T cell lymphoma (ENKTCL), a type of non-Hodgkin lymphoma, being investigated in the CITADEL trial.

We have recently expanded indications under study to include EBV-positive diffuse large cell lymphoma (DLBCL), Hodgkin lymphoma and post-transplant lymphoproliferative disease (PTLD), which are being investigated in the CIVIC trial.